LEXICON PHARMACEUTICALS INC (LXRX) Stock News
NASDAQ:LXRX - Nasdaq - US5288723027 - Common Stock
LXRX Latest News and Analysis
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
Event will feature insights on LX9211, Lexicon’s novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNP
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
Event will feature insights on LX9211, Lexicon’s novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNP...
Lexicon Appoints Scott Coiante as Chief Financial Officer
Lexicon Appoints Scott Coiante as Chief Financial Officer
THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the appointment of Scott Coiante as...
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
Confirms Previously Disclosed and Anticipated FDA Decision
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
Confirms Previously Disclosed and Anticipated FDA Decision...
2 Generic Drug Stocks Ready to Surge in 2025
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Strong Interest in Trial Participation Resulted in Enrollment Exceeding Target by 20 Percent and Completion Ahead of Schedule Top-line Data...
Lexicon Pharmaceuticals to Participate in December Investor Conferences
Lexicon Pharmaceuticals to Participate in December Investor Conferences
THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including...
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
Implementing Strategic Restructuring to Eliminate Commercial Organization and Rationalize Operations Across All Functions Prioritizing Strong R&D...
Lexicon Appoints Ivan H. Cheung to Board of Directors
Lexicon Appoints Ivan H. Cheung to Board of Directors
THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Ivan H. Cheung has been elected...
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago
Study results add to the growing body of evidence differentiating sotagliflozin within SGLT inhibitor class...
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA™ FDA Advisory...
Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease
People with T1D and CKD treated with sotagliflozin and insulin had similar lowering effects on glycated hemoglobin (HbA1c), the primary endpoint, as people...
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease
PDUFA target action date set for December 20, 2024...
Notable Wednesday Option Activity: SNOW, MDB, LXRX
New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024
Post hoc analysis evaluated sotagliflozin in patients with diabetic kidney disease (DKD)...
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe
-Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone payments...
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe
/PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has entered into an exclusive licensing agreement with Lexicon...
Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing...